A method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine
Using inexpensive and readily available 2-hydroxynicotinic acid as a starting material, a six-step reaction was employed to synthesize 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine, solving the problems of high cost and heavy metal residue in existing technologies. This method is efficient, low-cost, and suitable for commercial production.
Patent Information
- Application Number
- CN202611156152.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-31
- Publication Date
- 2026-11-17
AI Technical Summary
Existing methods for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine are costly and use heavy metal palladium catalysts, posing a risk of heavy metal residues and making them unsuitable for large-scale commercial production.
The target product was synthesized from inexpensive and readily available 2-hydroxynicotinic acid through a six-step reaction using a non-palladium catalyst and mild reaction conditions, including optimization of solvent, catalyst and acid-binding agent. Reactor equipment and conventional operation were used, and the product was finally purified by column chromatography and crystallization.
It achieves the synthesis of target products with high purity and high yield, reduces production costs, is suitable for large-scale commercial production, avoids heavy metal residues, and simplifies the separation and purification process of intermediates.
Smart Images

Figure CN123106523A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of organic chemical synthesis technology, specifically relating to a method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine. Background Technology
[0002] The pyridine structure in organic molecules has many positive effects in the biomedical field. Introducing a pyridine ring structure into drug molecules is an effective means to improve the biochemical efficacy and metabolic stability of drugs, which is related to the fact that pyridine structural fragments may participate in redox reactions in vivo (Ling et al., Drug Des Devel Ther 2021, 15, 4289–4338). In addition, the introduction of the pyridine ring structure can not only enhance cell permeability and repair protein binding problems (Pennington LD, Moustakas DT. J Med Chem. 2017, 60, 3552–3579), but also form various interactions with biological targets (such as enzymes, receptors, ion channels, etc.), enhancing the drug's targeting ability (Nasser et al., Future J Pharm Sci. 2021, 7, 24.).
[0003] Difluoromethoxy groups, being bioisosteres of methoxycarbonyl and formamide groups, play a crucial role in drug molecule design. Thanks to the high electronegativity and small atomic radius of fluorine atoms, replacing functional groups such as methoxycarbonyl and formamide groups with difluoromethoxy groups can effectively improve the lipophilicity and thermodynamic / chemical stability of drug molecules, thereby enhancing their biometabolizable properties. Furthermore, due to the unique properties conferred by oxygen and hydrogen atoms, difluoromethoxy groups possess the ability to act as both hydrogen bond acceptors and hydrogen bond donors. This means that difluoromethoxy groups can establish new interactions with protein active sites through weak intermolecular hydrogen bonding, demonstrating significant potential value in targeted drug design.
[0004] As claimed in the patent, the characteristic structure of compound 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine—the pyridine nitrogen heterocycle and the difluoromethoxy (OCF2H) functional group—has important applications in medicinal chemistry and is an important component of many drug molecules. Drug molecules that simultaneously possess both pyridine ring and difluoromethoxy structures already have practical applications. Roflumilast is an oral selective phosphodiesterase 4 (PDE4) inhibitor and is currently the only approved oral phosphodiesterase IV (PDE-4) inhibitor for the treatment of respiratory diseases, widely used in the treatment of chronic obstructive pulmonary disease; pantoprazole is a digestive system drug that inhibits gastric acid and has anti-ulcer properties, clinically applicable for the treatment of active peptic ulcers, gastric and duodenal ulcers, anastomotic ulcers, severe reflux esophagitis, Zollinger-Ellison syndrome, and acute upper gastrointestinal bleeding.
[0005] In recent years, the strategy of directly incorporating 2-difluoromethoxypyridine as a special functional structural module of drug molecules into drug design has received attention.
[0006] In 2012, Macsari's team, in their research on the potent, state-dependent blocking effect of 3-oxoisoindoline-1-carboxamide compounds on the biovoltage-gated sodium ion channel Nav1.7 and its analgesic effects in rats, discovered that introducing the 2-difluoromethoxypyridine structure into analgesics could greatly improve the selectivity of the drug for sodium ion channels Nav1.7 and Nav1.5, exhibiting excellent targeting ability (the half-maximal inhibitory concentrations (IC50) of Nav1.7 and Nav1.5 were 1.9 µM and 33 µM, respectively, at Vhold = -65 mV), and demonstrating excellent metabolic stability and good lipophilicity (Macsari et al., J. Med. Chem. 2012, 55, 6866−6880).
[0007] In 2021, Zafrania's team published a report (Zafrania et al., J.Med.Chem.2021,64,4516-453) showing that the lipophilicity of organic compounds methyl phenyl ether, difluoromethoxybenzene and 2-difluoromethoxypyridine increases in that order, and that the oxygen atom of 2-difluoromethoxypyridine has a certain hydrogen bond acceptor ability.
[0008] Invention patent CN115461327A discloses a potential potassium ion channel Kv7 opener, a spirocyclic derivative molecule that can be used to treat epilepsy. Experimental data show that some drug candidates with a 2-difluoromethoxypyridine structure exhibit extremely excellent pharmacodynamics and targeting ability. For example, the candidate molecule 1-[(R)-1-(2-difluoromethoxy-pyridin-4-yl)-2-methoxy-ethyl]-3-spiro[3.3]hept-2-yl-urea showed acute half-maximal inhibitory concentration (IC50) and half-maximal inhibitory concentration (IC50) after 20 minutes of experiment in a Kv7-dependent calcium oscillation inhibition assay in neurons in rats, respectively, at only 2.7 nM and 3.9 nM, indicating that it may have excellent pharmacodynamics. Furthermore, experiments revealed that 1-[(R)-1-(2-difluoromethoxy-pyridin-4-yl)-2-methoxy-ethyl]-3-spiro[3.3]hept-2-yl-urea exhibited a high shift value (shift value = (IC50 acute value [nM] in the presence of 10 μM X E-991) / (IC50 acute value [nM])) of up to 2616, demonstrating excellent targeting ability.
[0009] Among the amide-based heterocyclic metalloproteinase inhibitor compounds disclosed in US2007 / 0155738A1 and US2009 / 312312A1, some candidate drug molecules contain a difluoromethoxypyridine structural fragment, which are potential targeted drugs for various diseases such as rheumatoid arthritis, osteoarthritis, and osteoporosis caused by the overexpression of matrix metalloproteinases and aggregates. 4-Cyano-2-difluoromethoxypyridine serves as an important intermediate, prepared by reacting commercially available 4-cyano-2-hydroxypyridine and dichlorodifluoromethane under alkaline, low-temperature conditions for half an hour, followed by microwave heating.
[0010] In summary, the 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine compound of the present invention, as an important building block for drug molecules, has great potential application value in the pharmaceutical field.
[0011] Currently, the mainstream method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine is to couple 2-bis(4-methoxybenzyl)amino-3-acetyl-5-chloropyridine with potassium hydroxide under palladium catalysis to form a phenol, and then attach a difluoromethyl ether to the phenolic hydroxyl group using methods such as difluorobromomethyl phosphate diethyl ester or sodium difluorochloroacetate. The palladium-catalyzed method is expensive due to the high price of palladium catalysts; secondly, palladium is a heavy metal, and in the later stages of drug preparation, it is necessary to strictly control heavy metal residues.
[0012] In summary, 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine has extremely high value in drug molecule design, but its synthetic method is singular and has many limitations. Therefore, developing a novel synthetic method for the efficient preparation of 2-difluoromethoxypyridine compounds is of great significance to promote the further derivatization and application of 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine compounds. Summary of the Invention
[0013] The present invention aims to provide a method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine, which has the advantages of simple operation, short synthetic route, high synthetic yield and low cost, and is suitable for commercial large-scale production.
[0014] To achieve the above objectives, the specific technical solution of the present invention is as follows:
[0015] A method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine includes the following steps:
[0016] S1. Add solvent 2-hydroxynicotinic acid to the reaction vessel, add NCS in 3 to 5 portions, keep warm for 4 hours and stir. After the reaction is completed, add water to precipitate the solid, and separate the solid and liquid to obtain 2-hydroxy-5-chloronicotinic acid.
[0017] S2. The 2-hydroxy-5-chloronicotinic acid prepared in S1 is added to the reaction solvent, and then the chlorinating agent and catalyst are added in sequence. After the reflux reaction and the liquid-phase derivatization controlled reaction are completed, the mixture is concentrated to obtain 2,5-dichloronicotinic acid chloride.
[0018] S3. Add the 2,5-dichloronicotinyl chloride obtained in S2 to an organic solvent, and then add anhydrous magnesium chloride, triethylamine and diethyl malonate in sequence to react. After the reaction is completed, add water to separate the layers to obtain an organic phase. Then concentrate the organic phase and add it to DMSO for decarboxylation to obtain 2,5-dichloro-3-acetylpyridine.
[0019] S4. Add the 2,5-dichloro-3-acetylpyridine obtained in S3, the reaction organic solvent and the acid-binding agent to the reaction vessel, then add di(4-methoxybenzyl)amine, heat the reaction until complete, then add water and centrifuge to obtain 2-di(4-methoxybenzyl)amino-3-acetyl-5-chloropyridine;
[0020] S5. DMSO, pure water, soluble base, copper catalyst and 2-di(4-methoxybenzyl)amino-3-acetyl-5-chloropyridine obtained in S4 were added to the reaction vessel. The reaction was heated until complete, quenched with ammonium chloride aqueous solution, extracted with ethyl acetate, washed with brine, dried and concentrated to prepare 2-di(4-methoxybenzyl)amino-3-acetyl-5-hydroxypyridine.
[0021] S6. First, add the organic solvent to the reaction vessel, then add the acid-binding agent and the 2-di(4-methoxybenzyl)amino-3-acetyl-5-hydroxypyridine prepared in S5, then pass difluorochloromethane through until the reaction is complete, add water to separate the layers, dry, filter and concentrate to obtain the product 2-di(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine.
[0022] The solvent in S1 is selected from DMF, NMP, DMA, and acetonitrile, with DMF being the preferred solvent.
[0023] In S2, the reaction solvent is selected from dichloroethane and toluene, the chlorination reagent is thionyl chloride, and the catalyst is DMF. Preferably, the reaction solvent is dichloroethane.
[0024] The organic solvent in S3 is selected from toluene and tetrahydrofuran, and preferably, toluene is selected as the organic solvent.
[0025] In the decarboxylation reaction of S3, hydrochloric acid is added to adjust the pH to 4-6.
[0026] In S4 and S6, the reaction organic solvent is selected from at least one of DMF, DMA, DMSO, NMP and acetonitrile, and the acid-binding agent in S4 and S6 is selected from one of potassium carbonate, sodium carbonate and triethylamine. Preferably, the reaction organic solvent in S4 is acetonitrile and the acid-binding agent is potassium carbonate.
[0027] The heating temperature in S4 is 60℃~90℃, preferably 78℃~85℃.
[0028] In S5, the ratio of DMSO to pure water is 2 to 6:1, and the soluble alkali in S5 is selected from at least one of lithium hydroxide, sodium hydroxide, and potassium hydroxide. Preferably, the ratio of DMSO to pure water is 4:1, and lithium hydroxide is selected as the soluble alkali.
[0029] The copper catalyst in S5 is the same copper catalyst used in the Ullman coupling system, referring to the catalytic system reported in Organic Letters, 2017, 19, 3033-3036.
[0030] The reaction temperature in S5 is 80℃~100℃, and the reaction time is 18h~36h. Preferably, the reaction temperature is 90℃ and the reaction time is 22h.
[0031] S6 also includes the following purification steps: The obtained 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine is crude, dark in color, and has a purity greater than 95%. It needs to be purified by column chromatography elution. The eluent for column chromatography is petroleum ether and ethyl acetate. Then, crystallization is performed to obtain a pale yellow solid product.
[0032] Beneficial effects:
[0033] This invention uses inexpensive and readily available 2-hydroxynicotinic acid as a starting material to synthesize the target product through a six-step reaction. The synthesis route is short, the process steps are simple, and it avoids high-risk and high-cost special reagents. The raw material cost is controllable, each step of the reaction is compatible with the reaction vessel equipment, the reaction conditions are mild and controllable, and it can achieve large-scale production of hundreds of liters, making it suitable for industrial applications.
[0034] The reaction is controlled using a central control method to ensure the endpoint is controlled, resulting in fewer side reactions, easy separation of intermediates, and the fact that some intermediates can be used in the next step of the reaction without complex purification. The final product is treated by column chromatography-crystallization, and the purity of the product can reach 99%.
[0035] The present invention has excellent reaction yields at each step and a considerable overall yield. The post-processing adopts conventional operations such as extraction and centrifugation, which makes the process highly operable, reduces production energy consumption and separation costs, and has commercial large-scale production value. Attached Figure Description
[0036] Figure 1 This is the hydrogen nuclear magnetic resonance spectrum of 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine, the purified product from Example 1.
[0037] Figure 2 This is a schematic diagram of the synthetic route of 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine, the purified product in Example 1. Detailed Implementation
[0038] To better understand the purpose, structure, and function of this invention, a method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine is described in further detail.
[0039] Example 1:
[0040] S1. Add 41 liters of DMF and 10.3 kg of 2-hydroxynicotinic acid to a 100-liter reactor. Control the temperature below 15°C. Add 11.86 kg of NCS in 5 portions. After the addition is complete, keep the mixture at this temperature for 4 hours with stirring. After the reaction is completed, add the reaction solution to 123 kg of water to precipitate the solid. Centrifuge, rinse with water, and spin dry to obtain 10.9 kg of 2-hydroxy-5-chloronicotinic acid, with a yield of 85%.
[0041] S2. 12.4 kg of 2-hydroxy-5-chloronicotinic acid prepared in S1 was added to 24.8 L of dichloroethane in a reaction vessel, along with 124 g of DMF. After heating to 50 °C, 40.6 kg of thionyl chloride was added dropwise. After the addition was complete, the mixture was kept warm and stirred for 2 h. The methanol-derived liquid phase reaction was completed under controlled conditions. All solvents were removed by vacuum distillation, and the product was concentrated to obtain 2,5-dichloronicotinic acid chloride.
[0042] S3. The 2,5-dichloronicotinyl chloride obtained in S2 was added to 60 L of toluene, followed by the addition of 3.5 kg of anhydrous magnesium chloride and 13.2 kg of triethylamine. The mixture was stirred at room temperature for 45 minutes, and then 10 kg of diethyl malonate was added dropwise. After the addition was complete, the mixture was stirred for 3 h. After the reaction was completed, 100 kg of water was added to separate the layers, and the organic phase was obtained. The aqueous phase was extracted with ethyl acetate. The organic phases were combined, washed with brine, dried with sodium sulfate, and the solvent was concentrated to obtain approximately 23 kg of a yellow solid crude intermediate. The crude intermediate was then added to DMSO, and the pH was adjusted to 5 with hydrochloric acid. The mixture was heated to 120 °C and stirred overnight. After the reaction solution was cooled, it was added to a mixture of 150 L of water and 100 L of ethyl acetate. The layers were separated, and the aqueous phase was extracted with 50 L of ethyl acetate. The organic phases were combined, washed with brine, dried with sodium sulfate, filtered, and concentrated to obtain 7 kg of the product 2,5-dichloro-3-acetylpyridine.
[0043] S4. In a 100-liter reactor, add 6.08 kg of 2,5-dichloro-3-acetylpyridine obtained in S3, 31 liters of acetonitrile, and 5.8 kg of potassium carbonate, then add 7.7 kg of di(4-methoxybenzyl)amine. Heat to 80°C and react until complete. Then add 160 kg of water and centrifuge to obtain 12 kg of wet product. After drying, obtain 10.5 kg of 2-di(4-methoxybenzyl)amino-3-acetyl-5-chloropyridine with a purity of 98% and a yield of 84%.
[0044] S5. In a 100-liter reactor, add 26 liters of DMSO, 6.3 kg of pure water, 50 g of ligand, 39.6 g of copper acetylacetone, 1.4 kg of lithium hydroxide, and 12.1 kg of 2-di(4-methoxybenzyl)amino-3-acetyl-5-chloropyridine obtained in S4. Heat to 90°C and maintain for 22 h. Cool down and quench with 90 liters of ammonium chloride aqueous solution. Extract with ethyl acetate, combine the organic phases, wash with brine, dry with sodium sulfate, and concentrate to obtain 10.9 kg of crude 2-di(4-methoxybenzyl)amino-3-acetyl-5-hydroxypyridine. After purification by column chromatography, obtain 9.2 kg of 2-di(4-methoxybenzyl)amino-3-acetyl-5-hydroxypyridine with a purity of 98.5% and a yield of 78%.
[0045] S6. First, add 24 liters of acetonitrile to a 100-liter reactor, then add 2.46 kg of anhydrous potassium carbonate and 4 kg of 2-di(4-methoxybenzyl)amino-3-acetyl-5-hydroxypyridine prepared in S5. Then, pass difluorochloromethane through the mixture until the reaction is complete. Add 30 kg of water to separate the phases. Extract the aqueous phase with 15 kg of methyl ether. Combine the organic phases and dry them with sodium sulfate. Filter the mixture and concentrate the filtrate to obtain the crude product. After purification by column chromatography, crystallize the crude product with petroleum ether to obtain 3.33 kg of yellow solid product 2-di(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine with a purity of 99% and a yield of 80%.
[0046] The product's 1H NMR spectrum is as follows Figure 1 As shown, the synthetic route of the compound structure is as follows: Figure 2 As shown.
[0047] It is understood that the present invention has been described through some embodiments, and those skilled in the art will recognize that various changes or equivalent substitutions can be made to these features and embodiments without departing from the spirit and scope of the invention. Furthermore, under the teachings of the present invention, these features and embodiments can be modified to adapt to specific situations and materials without departing from the spirit and scope of the invention. Therefore, the present invention is not limited to the specific embodiments disclosed herein, and all embodiments falling within the scope of the claims of this application are within the protection scope of the present invention.
Claims
1. A method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine, characterized in that, Includes the following steps: S1. Add solvent 2-hydroxynicotinic acid to the reaction vessel, add NCS in 3 to 5 portions, keep warm for 4 hours and stir. After the reaction is completed, add water to precipitate the solid, and separate the solid and liquid to obtain 2-hydroxy-5-chloronicotinic acid. S2. The 2-hydroxy-5-chloronicotinic acid prepared in S1 is added to the reaction solvent, and then the chlorinating agent and catalyst are added in sequence. After the reflux reaction and the liquid-phase derivatization controlled reaction are completed, the mixture is concentrated to obtain 2,5-dichloronicotinic acid chloride. S3. Add the 2,5-dichloronicotinyl chloride obtained in S2 to an organic solvent, and then add anhydrous magnesium chloride, triethylamine and diethyl malonate in sequence to react. After the reaction is completed, add water to separate the layers to obtain an organic phase. Then concentrate the organic phase and add DMSO to decarboxylate to obtain 2,5-dichloro-3-acetylpyridine. S4. Add the 2,5-dichloro-3-acetylpyridine obtained in S3, the reaction organic solvent and the acid-binding agent to the reaction vessel, then add di(4-methoxybenzyl)amine, heat the reaction until complete, then add water and centrifuge to obtain 2-di(4-methoxybenzyl)amino-3-acetyl-5-chloropyridine; S5. DMSO, pure water, soluble base, copper catalyst and 2-di(4-methoxybenzyl)amino-3-acetyl-5-chloropyridine obtained in S4 were added to the reaction vessel. The reaction was heated until complete, quenched with ammonium chloride aqueous solution, extracted with ethyl acetate, washed with brine, dried and concentrated to prepare 2-di(4-methoxybenzyl)amino-3-acetyl-5-hydroxypyridine. S6. First, add the organic solvent to the reaction vessel, then add the acid-binding agent and the 2-di(4-methoxybenzyl)amino-3-acetyl-5-hydroxypyridine prepared in S5, then pass difluorochloromethane through until the reaction is complete, add water to separate the layers, dry, filter and concentrate to obtain the product 2-di(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine.
2. The method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine according to claim 1, characterized in that, The solvent in S1 is selected from DMF, NMP, DMA, and acetonitrile.
3. The method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine according to claim 1, characterized in that, The reaction solvent in S2 is selected from dichloroethane and toluene, the chlorination reagent is thionyl chloride, and the catalyst is DMF.
4. The method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine according to claim 1, characterized in that, The organic solvent in S3 is selected from toluene and tetrahydrofuran.
5. The method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine according to claim 1, characterized in that, The reaction organic solvents in S4 and S6 are selected from at least one of DMF, DMA, DMSO, NMP and acetonitrile, and the acid-binding agents in S4 and S6 are selected from one of potassium carbonate, sodium carbonate and triethylamine.
6. The method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine according to claim 1, characterized in that, The heating temperature in S4 is 60℃~90℃.
7. The method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine according to claim 1, characterized in that, The ratio of DMSO to pure water in S5 is 2 to 6:1, and the soluble alkali in S5 is selected from at least one of lithium hydroxide, sodium hydroxide, and potassium hydroxide.
8. The method for synthesizing 2-bis(4-methoxybenzyl)amino-3-acetyl-5-difluoromethoxypyridine according to claim 1, characterized in that, The reaction temperature in S5 is 80℃~100℃, and the reaction time is 18h~36h.
Citation Information
Patent Citations
Spirourea derivatives
CN115461327A
Heterobicyclic Metalloprotease Inhibitors
US20090312312A1
